5. Needle-free electronically-controlled jet injector treatment with bleomycin is efficacious and well-tolerated in patients with severe keloids: results of a randomized, double-blind, placebo-controlled trial. 134 Table 2. Analysis results of 3D imaging, perfusion and POSAS measurements. Data is presented as LS mean, Δ representing LSM change from baseline, 95% confidence interval and a p-value (Bleomycin-Placebo). *p-value comparing Δ values at follow-up in control versus intervention. Bleomycin Placebo Day 0 Δ Day 29 Δ Day 57 Δ Day 85 Day 0 Δ Day 29 Δ Day 57 Δ Day 85 p- value* Volume (mm3) 465.38 -46.64 (-76.78, -16.51) -76.25 (-106.67, -45.84) -91.90 (-122.32, -61.48) 465. 38 -2.11 (-33.07, 28.85) 0.66 (-30.26, 31.59) 13.44 (-17.01, 43.90) <0.01 Height (mm) 1.26 -0.14 (-0.24, -0.04) -0.25 (-0.35, -0.15) -0.30 (-0.40, -0.20) 1.26 0.00 (-0.10, 0.10) 0.02 (-0.08, 0.13) 0.05 (-0.05, 0.15) 0.0015 Basal Flow (AU) 120.41 4.05 (-4.34, 12.43) -7.19 (-15.58, 1.19) -9.73 (-18.28, -1.18) 120. 41 6.70 (-1.70, 15.09) -3.69 (-12.09, 4.70) -2.18 (-10.73, 6.37) 0.1630 Total POSAS Observer 41.0 -1.5 (-2.9, -0.1) -4.3 (-5.7, -2.9) -8.4 (-9.8, -6.9) 41.0 -1.6 (-3.1, -0.2) -1.6 (-3.1, -0.2) -1.6 (-3.0, -0.1) 0.0011 Total POSAS patient 47.3 -11.6 (-15.5, -7.7) -11.3 (-15.2, -7.4) -13.3 (-17.3, -9.4) 47.3 -12.3 (-16.2, -8.4) -9.7 (-13.6, -5.9) -7.8 (-11.8, -3.9) 0.0344
RkJQdWJsaXNoZXIy MTk4NDMw